Computers Pass Dosage Test For Thrombosis Drugs

Increasing evidence of the value of these anticoagulant drugs in a wide range of clinical disorders such as abnormal heart rhythm, or atrial fibrillation, has led to a rapid rise in their use around the world.

However, prescribing the right oral dose of anticoagulant to patients, even for experienced medical staff, can be problematic as individuals differ greatly in response to a given dose: too high a dose for an individual and the blood becomes too thin and can lead to internal bleeding, too low and the blood clots too readily.

Previous studies supporting the use of computer-assisted dosage have depended solely on laboratory results and have not been sufficiently large to determine whether observed improvements in normal blood clotting time -- known as the 'international normalised ratio' or INR -- resulted in clinical benefit and improved safety.

But now results from a four-year clinical trial organised from The University of Manchester have shown that computer-assisted dosage is as good, if not better, at prescribing the correct dosage to normalise and maintain the correct INR in patients as dosages given by medical professionals.

"The need for computer assistance arises from the massive demand for oral anticoagulants following their success at treating an increasing number of thrombotic and embolic conditions," said Professor Leon Poller, who headed the research in Manchester's Faculty of Life Sciences.

"This increased demand has been overwhelming and stretched medical facilities worldwide to their limits. Computer dosage was introduced as a way to meet this demand but its safety and effectiveness had never been established."

The study, carried out in 32 medical centres across the European Union and involving more than 13,000 patients, analysed nearly 400,000 INR tests, divided evenly between manual and computer-assisted dosage.

The percentage of manual tests to give the correct INR was 64.7%, compared to 65.9% for computer-assisted dosage, confirming the effectiveness of the two programs tested by the team.

In terms of safety, the number of INR tests that resulted in clinical complications was 7.6% lower in all clinical groups with computer-assisted dosage, dispelling any safety concerns.

Indeed, while this overall figure may not be deemed significant, in the 3,208 patients with deep vain thrombosis or pulmonary embolism, the number of clinical events following treatment were significantly lower for computer dosage -- 9.1 per 100 patient-years with medical staff dosage was reduced to 6.1 in the computer arm.

"The results are even more impressive when you consider that the comparisons were made against medical professionals based at centres that specialised in prescribing oral anticoagulants," said Professor Poller.

"At the very least, our study confirms the clinical safety and effectiveness of computer-assisted dosage using the two systems we tested and should help to bring relief to overstretched medical professionals while providing reassurance to patients."

Background information

The 32 centres with a special interest in oral anticoagulation recruited 13,219 patients, providing 18,617 patient-years.

INR tests numbered 193,890 with manual dosage and 193,424 with computer-assistance, giving 'time-in-range' of 64.7% and 65.9% respectively.

The two computer programs tested were PARMA 5 and DAWN AC.

The results of the study have just been presented to the International Society on Thrombosis and Haemostasis conference in Geneva, Switzerland.